Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748308 | 0.84 | MAPT (0.54) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748301 | 0.82 | KDM4E (0.43) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748239 | 0.82 | KMT2A (0.43) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748255 | 0.78 | MAPT (0.41) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748325 | 0.73 | PTGS2 (0.47) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748238 | 0.71 | MAPT (0.38) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL11971440 | 0.71 | ALDH1A1 (0.47) | GAANPSR1KDM4ERXFP1PSMB5 | |
| SCHEMBL20881196 | 0.71 | CYP1A2 (0.42) | GAANPSR1KDM4ERXFP1PSMB5 | |
| SCHEMBL23748305 | 0.71 | MAPT (0.39) | GAANPSR1KDM4ERXFP1MAPT | |
| SCHEMBL23748312 | 0.70 | MAPT (0.46) | GAANPSR1KDM4ERXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) | 2024-10-01 | — | — | US | disclosed |
| EP-3863632-B1 | QUINOLYLNITRONE FOR USE IN THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA | ISQUAEMIA BIOTECH S L (ES) | 2023-06-07 | — | — | EP | disclosed |
| US-20210330662-A1 | QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA | ISQUAEMIA BIOTECH, S.L. (ES) | 2021-10-28 | — | — | US | disclosed |
| EP-3863632-A1 | QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA | Isquaemia Biotech, S.L. (ES) | 2021-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102631-B2 | Quinolylnitrones for the treatment and prevention of a cerebral stroke or ischaemia | NLN, TXN2, TXN | GAA 222/4885NPSR1 1088/4885KDM4E 4281/4885 |
| US-20210330662-A1 | QUINOLYLNITRONES FOR THE TREATMENT AND PREVENTION OF A CEREBRAL STROKE OR ISCHAEMIA | NLN, TXN2, TXN | GAA 222/4885NPSR1 1088/4885KDM4E 4281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.